

FORMULATION OF VALSARTAN ORODISPERSIBLE TABLETS BY USING NEW GENERATION SUPERDISINTEGRANTS

Hareesh dara^{1*}, Raidi vamshi krishna², Meesa Rajendar², Guntheti chiranjeevi¹

Sree College of Pharmacy, Nayakulagudem, Kothagudem, Telangana.

*Corresponding Author Email: dara.hari@gmail.com

ABSTRACT

In the present work, an attempt has been made to develop fast disintegrating tablets of Valsartan. New generation super disintegrates Solutab, Explotab and Polyplasdone XL was selected as super disintegrates. All the formulations were prepared by direct compression method using 6mm punch on 8 station rotary tablet punching machine. The blend of all the formulations showed good flow properties such as angle of repose, bulk density, tapped density. The prepared tablets were shown good post compression parameters and they passed all the quality control evaluation parameters as per I.P limits. Among all the formulations F4 formulation showed maximum % drug release i.e., 97.54 % in 10 min hence it is considered as optimized formulation. The f4 formulation contains Solutab as super disintegrate in the concentration of 20 mg.F8 formulation also showed maximum percentage drug release i.e., 101.8% in 10 min ,it contains Explotab as super disintegrate in the concentration of 20 mg.

KEY WORDS

Valsartan, Oro disintegrating tablets, Explotab, Solutab, Polyplasdone XL

INTRODUCTION

Despite of tremendous advancements in drug delivery, the oral route remains the perfect route for the administration of therapeutic agents because the low cost of therapy, ease of administration lead to high levels of patient compliance.



Fig 1: Fast dissolving tablets

It is always the aim of a scientist or a dosage form designer to enhance the safety of a drug molecule while maintaining its therapeutic efficacy. Recent advances in NDDS aim for the same by formulating a dosage form,

convenient to be administered so as to achieve better patient compliance. Mouth Dissolving Tablet (MDT) is one among such approaches ¹.

Improved patient compliance has achieved enormous demand. Consequently, demand for their technologies is also increasing many folds. To develop a chemical entity, a lot of money, hard work and time are required. So, focus is rather being laid on the development of new drug delivery systems for already existing drugs, with enhanced efficacy and bioavailability, thus reducing the dose and dosing frequency to minimize the side effects. Super disintegrants provide quick disintegration due to combined effect of swelling and water absorption by the formulation. Due to swelling of superdisintegrants, the wetted surface of the carrier increases, which promotes the wettability and dispersibility of the system, thus enhancing the disintegration and dissolution. combination of losartan is used for treating high blood pressure. Losartan is an oral medication that

belongs to a class of drugs called angiotensin receptor blockers (ARBs). Angiotensin, formed in the blood by the action of angiotensin converting enzyme (ACE), is a powerful chemical that attaches to angiotensin receptors found in many tissues but primarily on smooth muscle cells surrounding blood vessels. Angiotensin's attachment to the receptors causes the muscles to contract and the blood vessels to narrow (vasoconstrict) which leads to an increase in blood pressure (hypertension). Losartan (more specifically, the chemical formed when the liver converts the inactive losartan into an active chemical) blocks the angiotensin receptor. By blocking the action of angiotensin, losartan relaxes the muscles, dilates blood vessels and thereby reduces blood pressure

MATERIALS

The Valsartan drug was obtained as gift sample from hetero labs and all other excipients including super disintegrants solutab, explotab, polyplasdone XL, magnesium stearate, talc, MCC pH 102 were obtained from merck specialties pvt ltd, Mumbai, india.

Methodology:

Tablet formulation:

Formulation of Valsartan Dispersible Tablet by Direct-Compression ⁷:

Composition of preliminary trials for Valsartan Dispersible Tablet by direct compression is shown in table 6.1. All the ingredients were weighed. Required quantity of drug and excipient mixed thoroughly in a polybag. The blend is compressed using rotary tablet machine-10 station with 6mm flat punch, B tooling. Each tablet contains 2.5 mg Valsartan and other pharmaceutical ingredients.

Table 1. Formulation of Valsartan oro dispersible tablets

INGREDIENT	F ₁	F ₂	F ₃	F ₄	F ₅	F ₆	F ₇	F ₈	F ₉	F ₁₀	F ₁₁	F ₁₂
Valsartan	25	25	25	25	25	25	25	25	25	25	25	25
Solutab	5	10	15	20								
Explotab					5	10	15	20				
PolyplasdoneXL									5	10	15	20
Talc	2	2	2	2	2	2	2	2	2	2	2	2
Mg. Stearate	2	2	2	2	2	2	2	2	2	2	2	2
MCC pH102	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S	Q.S
TOTAL	100	100	100	100	100	100	100	100	100	100	100	100

All ingredients are expressed in mg only

Evaluation parameters:

Precompression parameters ^{9,10}:

1. Bulk Density (D_b):

It is the ratio of total mass of powder to the bulk volume of powder. It was measured by pouring the weight powder (passed through standard sieve # 20) into a measuring cylinder and initial weight was noted. This initial volume is called the bulk volume. From this the bulk density is calculated according to the formula mentioned below. It is expressed in g/ml and is given by,

$$D_b = M / V_b$$

Where, M is the mass of powder

V_b is the bulk volume of the powder.

2. Tapped Density (D_t):

It is the ratio of total mass of the powder to the tapped volume of the powder. Volume was measured by tapping the powder for 750 times and the tapped

volume was noted if the difference between these two volumes is less than 2%. If it is more than 2%, tapping is continued for 1250 times and tapped volume was noted. Tapping was continued until the difference between successive volumes is less than 2 % (in a bulk density apparatus). It is expressed in g/ml and is given by,

$$D_t = M / V_t$$

Where,

M is the mass of powder

V_t is the tapped volume of the powder.

3. Angle of Repose (Θ):

The friction forces in a loose powder can be measured by the angle of repose (q). It is an indicative of the flow properties of the powder. It is defined as maximum angle possible between the surface of the pile of powder and the horizontal plane

$$\tan(\Theta) = h / r$$

$$\Theta = \tan^{-1} (h / r)$$

Where,

Θ is the angle of repose.

h is the height in cm

r is the radius in cm

The powder mixture was allowed to flow through the funnel fixed to a stand at definite height (h). The angle of repose was then calculated by measuring the height and radius of the heap of powder formed. Care was taken to see that the powder particles slip and roll over each other through the sides of the funnel. Relationship between angle of repose and powder flow property.

Table 2: Angle of Repose as an Indication of Powder Flow Properties

Sr. No.	Angle of Repose ($^{\circ}$)	Type of Flow
1	<20	Excellent
2	20-30	Good
3	30-34	Passable
4	>34	Very Poor

Carr's index (or) % compressibility:

It indicates powder flow properties. It is expressed in percentage and is given by,

$$I = \frac{D_t - D_b}{D_t} \times 100$$

Where,

D_t is the tapped density of the powder and

D_b is the bulk density of the powder.

Table 3 Relationship between % compressibility and flow ability

Sr no.	% Compressibility	Flow ability
1	5-12	Excellent
2	12-16	Good
3	18-21	Fair Passable
4	23-35	Poor
5	33-38	Very Poor
6	<40	Very Very Poor

5. Hausner ratio:

Hausner ratio is an indirect index of ease of powder flow. It is calculated by the following formula.

$$\text{Hausner ratio} = \frac{D_t}{D_b}$$

Where, D_t is the tapped density, D_b is the bulk density.

Lower Hausner ratio (<1.25) indicates better flow properties than higher ones (>1.25).

Post compression parameters:

1. Weight variation:

20 tablets were selected randomly from the lot and weighted individually to check for weight variation. Weight variation specification as per I.P. is shown in table No. 4.

Table 4 Weight Variation Specification as per IP

Average Weight of Tablets	%Deviation
80 mg or less	± 10
More than 80 mg but less than 250 mg	± 7.5
250 mg or more	± 5

Hardness:

Hardness or tablet crushing strength (fc), the force required to break a tablet in a diametric compression was measured using Monsanto tablet hardness tester. It is expressed in kg/cm².

Thickness:

Three tablets were selected randomly from each batch and thickness was measured by using Vernier Caliper.

Friability (F):

Friability of the tablet determined using Roche friabilator. This device subjects the tablet to the combined effect of abrasion and shock in a plastic chamber revolving at 25 rpm and dropping a tablet at the height of 6 inches in each revolution. Pre weighed sample of tablets was placed in the friabilator and were subjected to the 100 revolutions. Tablets were dusted using a soft muslin cloth and reweighed. The friability (F) is given by the formula.

$$F = \frac{W_{\text{initial}} - W_{\text{final}}}{W_{\text{initial}}} \times 100$$

Determination OF UV Absorption maxima:

Valsartan solution was prepared in 0.1 N HCL and diluted suitably. The UV spectrum of the solution was taken on Lab India 3200 UV/Vis double beam Spectrophotometer. The Solution exhibited UV maxima at 244 nm.

Preparation of Standard Calibration Curve of Valsartan:

100 mg of Valsartan was accurately weighed and dissolved in little amount of Methanol and make up the final volume up to 100 ml with 0.1 N HCL (pH 1.2) to prepare stock solution. The 10 ml of stock solution was further diluted with 0.1 N HCL (pH 1.2) in 100ml to get 100µg/ml (working standard). Then 0.5,1,1.5,2,2.5 ml of working standard was taken in 10 ml standard volumetric flask and made up the volume with 0.1N HCL to prepare 5µg,10µg,15µg,20µg, and 25µg drug per ml

solution. Then the absorbance was measured in a UV spectrophotometer at 244 nm against 0.1 N HCL (pH 1.2) as blank. The absorbance so obtained was tabulated as in Table 5 Calibration curve was constructed and shown in Fig.2.

In-Vitro drug release:

Release of the drug *in vitro*, was determined by estimating the dissolution profile.

Dissolution test:

USP II Paddle apparatus was used and paddle was allowed to rotate at 50 rpm, acid buffer 0.1N HCL (pH 1.2, 900 ml) was used as a dissolution medium.

Assay:

10 tablets were weighed and triturated. The tablet triturate equivalent to 10 mg of the drug was weighed accurately, dissolved in pH 1.2 buffer and diluted to 100 ml with the same. Further dilutions were done suitably to get a concentration of 10 µg/ ml with simulated gastric fluid pH 1.2. Absorbance was read at 244 nm against the reagent blank, and the concentrations of VALSARTAN in µg/ ml was determined by using the regression equation.

Drug content in mg / tablet = conc. µg/ml * dilution factor

% Drug content = drug content in mg * 100 / label claim.

Drug- excipient compatibility studies by FT-IR:

The compatibility between the pure drug and excipients was detected by FTIR spectra obtained on Bruker FTIR Germany (Alpha T). The potassium bromide pellets were prepared on KBr press by grounding the solid powder sample with 100 times the quantity of KBr in a mortar. The finely grounded powder was then introduced into a stainless-steel die and was compressed between polished steel anvils at a pressure of about 8t/in². The spectra were recorded over the wave number of 8000 to 400cm⁻¹.

RESULTS AND DISCUSSION

Standard Calibration curve of Valsartan ^{4,5}:

Table 5: Concentration and absorbance obtained for calibration curve of Valsartan in 0.1 N hydrochloric acid buffer (pH 1.2)

S. No.	Concentration (µg/ml)	Absorbance* (at 244 nm)
1	5	0.227
2	10	0.406
3	15	0.621
4	20	0.824
5	25	0.957

It was found that the estimation of Valsartan by UV spectrophotometric method at $\lambda_{\max}$ 244.0 nm in 0.1N Hydrochloric acid had good reproducibility and this method was used in the study. The correlation

coefficient for the standard curve was found to be closer to 1, at the concentration range, 5- 25 μ g/ml. The regression equation generated was $y = 0.0376x + 0.0436$.




Fig 2: standard graph of Valsartan in 0.1 N HCl

Evaluation Parameters for Fast Dissolving Tablets of Valsartan:

Pre-compression parameters:

The data were shown in Table 7.2. The values for angle of repose were found in the range of 25°-30°. Bulk densities and tapped densities of various formulations were found to be in the range of 0.41 to 0.50 (gm/cc)

and 0.50 to 0.58 (gm/cc) respectively. Carr's index of the prepared blends were fall in the range of 13.06% to 18.18%. The Hausner ratio were fall in range of 1.14 to 1.22. From the result it was concluded that the powder blends had good flow properties, and these can be used for tablet manufacture.

Table 6: Pre-compression parameters

Formulations	Bulk Density (gm/cm ²)	Tap Density (gm/cm ²)	Carr's Index (%)	Hausner ratio	Angle Of Repose(θ)
F ₁	0.45	0.55	18.18	1.22	27.91
F ₂	0.47	0.55	14.54	1.17	28.23
F ₃	0.50	0.58	13.79	1.16	29.34
F ₄	0.46	0.55	16.36	1.19	26.71
F ₅	0.50	0.58	13.79	1.16	29.34
F ₆	0.47	0.55	14.54	1.17	28.23
F ₇	0.50	0.58	13.79	1.16	29.34
F ₈	0.41	0.50	18	1.21	26.78
F ₉	0.43	0.50	14	1.16	26.78
F ₁₀	0.42	0.51	18.24	1.20	26.68
F ₁₁	0.48	0.56	18.12	1.21	26.70
F ₁₂	0.41	0.54	18.11	1.22	26.71

Post compression Parameters^{9,10}:

Weight variation test:

Tablets of each batch were subjected to weight variation test, difference in weight and percent deviation was calculated for each tablet and was shown

in the Table 9. The average weight of the tablet is approximately in range of 107 to 98.5, so the permissible limit is $\pm 10\%$ (110-90mg). The results of the test showed that, the tablet weights were within the pharmacopoeia limit.

Hardness test:

Hardness of the three tablets of each batch was checked by using Pfizer hardness tester and the data's were shown in Table 9. The results showed that the hardness of the tablets is in range of 2.0 to 2.5 kg/cm², which was within IP limits.

Thickness:

Thickness of three tablets of each batch was checked by using Vernier Caliper and data shown in Table-9 The result showed that thickness of the tablet is raging from 3.56 to 3.64.

Friability:

Tablets of each batch were evaluated for percentage friability and the data's were shown in the Table 9. The average friability of all the formulations lies in the range of 0.30 to 0.51% which was less than 1% as per official requirement of IP indicating a good mechanical resistance of tablets.

Table 7 Post-Compression parameters:

FD	Weight variation (mg)	Hardness (kg/cm ²)	Thickness (mm)	Disintegration Time (sec)	Friability (%)	Assay (%)
F ₁	105.5	2.5	3.59	20.33	0.43	97.23
F ₂	104.3	2.4	3.64	22.66	0.34	98.55
F ₃	110.5	2.5	3.59	30.33	0.49	98.16
F ₄	109.3	2.3	3.58	19.00	0.47	99.34
F ₅	99.4	2.3	3.59	30.33	0.49	98.16
F ₆	102.1	2.4	3.64	22.66	0.34	98.55
F ₇	101.3	2.5	3.59	30.33	0.49	98.16
F ₈	107.7	2.4	3.56	17.00	0.34	99.25
F ₉	102.5	2.5	3.56	17.00	0.34	99.25
F ₁₀	103.8	2.4	3.55	15.99	0.43	98.6
F ₁₁	102.4	2.8	3.45	15.00	0.54	98.7
F ₁₂	98.5	2.5	3.54	16.76	0.43	98.5

In vitro disintegration time:

Tablets of each batch were evaluated for in vitro disintegration time and the data's were shown in the

Table 8. The results showed that the disintegration time of prepared tablets were in the range of 12.66 to 30.33 seconds.

Time (Min)	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
5	25.4	30.8	45.72	75.33	24.3	31.7	48.3	60.23	14.9	28.4	39.5	78.9
10	39.6	36.72	66.16	97.54	31.6	34.5	82.9	101.8	28.4	35.2	76.3	89.4
15	48.6	56.16	101.16		49.3	41.9	98.7		33.1	48.9	96.2	99.2
20	64.3	87.4			58.3	62.4			59.7	66.8	99.7	
25	76.4	98.5			74.3	89.1			79.3	78.1		
30	97.6				88.1	99.5			88.9	86.4		

Assay: Assay studies were performed for the prepared formulations. From the assay studies it was concluded that all the formulations were showing the % drug content values within 97.23 -99.25 %.

Table 9 In vitro Dissolution studies:

Time (Min)	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10	F11	F12
5	25.4	30.8	45.72	75.33	24.3	31.7	48.3	60.23	14.9	28.4	39.5	78.9
10	39.6	36.72	66.16	97.54	31.6	34.5	82.9	101.8	28.4	35.2	76.3	89.4
15	48.6	56.16	101.16		49.3	41.9	98.7		33.1	48.9	96.2	99.2
20	64.3	87.4			58.3	62.4			59.7	66.8	99.7	
25	76.4	98.5			74.3	89.1			79.3	78.1		
30	97.6				88.1	99.5			88.9	86.4		

In vitro Dissolution studies:

Invitro dissolution studies were carried out by using 900ml of 0.1 N HCl in USP dissolution apparatus by using

paddle method. The dissolution studies were carried out for about 30 min. The dissolution data for all the formulations were given in the Table 9.

Fig 3: Dissolution profile of formulations prepared with Solutab as super disintegrate




Fig 4: Dissolution profile of formulations prepared with Explotab as super disintegrate





Fig 5: Dissolution profile of formulations prepared with Polyplasdone XL as super disintegrate



From the table10 it was evident that the formulations prepared with super disintegrate Solutab showed maximum % drug release in 10 min i.e.97.54% (F4 formulation and the concentration of super disintegrate is 20 mg).The formulations prepared with Explotab showed maximum percentage drug release in 10 min i.e., 101.8 % (F8 formulation and the concentration of super disintegrate is 20 mg).The formulation's prepared

with Polyplasdnone XL showed maximum percentage drug release in 15 min i.e.,99.2%.

Irrespective of super disintegrate type the disintegration time decreases and Dissolution time also decreases as the concentration of super disintegrate increases. The dissolution profile was represented in above graphs.

Fourier Transform-Infrared Spectroscopy:

Figure 6: FT-TR Spectrum of Valsartan pure drug.





Figure 7 : FT-IR Spectrum of Optimized Formulation



CONCLUSION

In the present work, an attempt has been made to develop fast disintegrating tablets of Valsartan. New generation super disintegrates Solutab, Explotab and Polyplasdnone XL was selected as super disintegrates. All the formulations were prepared by direct compression method. The blend of all the formulations showed good flow properties such as angle of repose, bulk density, tapped density. The prepared tablets were shown good post compression parameters and they passed all the quality control evaluation parameters as per I.P limits. Among all the formulations F4 formulation showed

maximum % drug release i.e., 97.54 % in 10 min hence it is considered as optimized formulation. The f4 formulation contains Solutab as super disintegrate in the concentration of 20 mg. F8 formulation also showed maximum percentage drug release i.e., 101.8% in 10 min, it contains Explotab as super disintegrate in the concentration of 20 mg.

REFERENCES

1. Chein YW. Oral Drug Delivery and Delivery Systems. 2nd ed. New York: Marcel Dekker; 1992.

2. Kaur T, Bhawandeep G, Sandeep K, Gupta GD. Mouth dissolving tablets: a novel approach to drug delivery. *Int J Curr Pharm Res.* 2011; 3(1): 1-7.
3. Augsburger LL, Stephen WH. Orally disintegrating tablets. *Pharmaceutical dosage forms: tablets.* Infoma Healthcare Publication, 3rd ed., 2; 293-312.
4. Schwartz BJ, Connor RE. Optimization technique in pharmaceutical formulations and processing. *Modern Pharmaceutics.* 3rd ed. Marcel Dekker Inc. New York; 1996; 607-24.
5. Bolton S. *Pharmaceutical statistics- Practical and clinical applications.* 3rd ed. Marcel Dekker Inc. New York; 1997.
6. Goodman and Gilman, the pharmacological basis of therapeutics, Joel G. Hardman edition, 10th ed., Mc Graw Hill publication; 1250-56.
7. Jain CP, Naruka PS. Formulation and evaluation of fast dissolving tablets of valsartan. *Int J Pharm Pharmaceutical sci.* 2009 July-Sep; 1(1): 219-26.
8. Lachman L, Liberman HA and Kanig JL. *Theory & practice of industrial pharmacy.* 3rd ed. Mumbai: Varghese publishing house; 1991: 296-302.
9. *Indian pharmacopoeia*, Govt. of India, ministry of health and family welfare. New Delhi: The controller of publications; 1996.

Corresponding Author:*Hareesh Dara***Email: dara.hari@gmail.com